SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-057117
Filing Date
2023-11-01
Accepted
2023-11-01 07:02:15
Documents
79
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q apls-20230930.htm   iXBRL 10-Q 2917189
2 EX-31.1 apls-ex31_1.htm EX-31.1 18529
3 EX-31.2 apls-ex31_2.htm EX-31.2 17931
4 EX-32.1 apls-ex32_1.htm EX-32.1 9934
5 EX-32.2 apls-ex32_2.htm EX-32.2 10079
  Complete submission text file 0000950170-23-057117.txt   10613106

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT apls-20230930_def.xml EX-101.DEF 218303
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT apls-20230930_lab.xml EX-101.LAB 528733
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT apls-20230930_cal.xml EX-101.CAL 64810
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT apls-20230930.xsd EX-101.SCH 79428
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT apls-20230930_pre.xml EX-101.PRE 378777
73 EXTRACTED XBRL INSTANCE DOCUMENT apls-20230930_htm.xml XML 1964871
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

IRS No.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38276 | Film No.: 231366519
SIC: 2834 Pharmaceutical Preparations